Quantum Flex^® Data for Multiple Size Bioreactors Showing Rapid T-Cell Expansion to Numbers Equivalent to a Therapeutic Dose - 23 February 2023

Terumo Blood and Cell Technologies’ IMUGARD Platelet Pooling Set Cleared by FDA - 14 February 2023

Essential Cell Collection Considerations for Immune Cell Therapy - 12 January 2023

Automated Data Management — and the Role It Can Play in Blood Center Staff Retention - 5 December 2022

Donation to Blood Emergency Readiness Corps Supports an Adequate U.S. Blood Supply - 30 November 2022

Terumo Blood and Cell Technologies Announces Sale of the Autologous Biologics Business Unit to Global Medical Inc. - 09 November 2022

Have We Reached a New Turning Point in Whole Blood Processing? - 07 November 2022

Using Automated Data Collection and Device Connectivity to Improve Donor Safety - 17 October 2022

Terumo Blood and Cell Technologies launches Quantum Flex bioreactor platform, one of the first systems that enables cell therapy commercialization from process development through manufacturing - 19 September 2022

Relating to Blood Donors: the importance of understanding donor personas - 17 August 2022

Rika Plasma Donation System Reaches Critical Milestone with Plasma Collection from First Donor - 4 August 2022

Collaboration with Eliaz Therapeutics in the development of a novel therapeutic apheresis treatment for acute kidney injury (AKI) - 26 July 2022

How scientific marketing benefits global community of caregivers and patients - 25 July 2022

Terumo Blood and Cell Technologies and GenCure collaborate to advance cell and gene therapy manufacturing solutions - 27 June 2022

NHS England chooses Spectra Optia^® Apheresis System as part of MedTech Funding Mandate for expansion of sickle cell disease treatment - 16 June 2022

Celebrating World Blood Donor Day 2022 - 10 June 2022

Terumo Blood and Cell Technologies Inaugurates Second Manufacturing Facility in Colorado - 25 May 2022

Terumo Blood and Cell Technologies Receives $10.6M Contract From U.S. Government to Continue Freeze-Dried Plasma Development - 26 April 2022

CEO Antoinette Gawin will serve as Group Managing Executive Officer in Terumo Corporation’s New Executive Officers’ Management System - 12 April 2022

Terumo Blood and Cell Technologies Appoints Gene Stellon to Lead Innovation and Development - 5 April 2022

Efforts to Boost Blood Donation Bolstered by Public Service Announcements - 4 January 2022

Automating fill and finish: Five steps for scaling success - 23 November 2021

Top three reasons why automated data acquisition is critical to fill and finish quality - 23 November 2021

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe - 16 November 2021

Action Center Set to Provide Grocery Boxes for 5,700 Meals This Thanksgiving - 4 November 2021

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX^® for ECP Administration with the THERAKOS^® CELLEX^® Photopheresis System for Chronic Graft Versus Host Disease in Adults - 28 October 2021

Medical innovation helps treatments reach patients faster - 18 October 2021

Terumo Blood and Cell Technologies is collaborating with BioCentriq to provide technologies and expertise to automate cell and gene therapy manufacturing - 7 October 2021

Terumo Blood and Cell Technologies Grant Supports Blood Donor Education Program About Diversity - 27 September 2021

Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare - 17 September 2021

Terumo Blood and Cell Technologies announces a new software update for its Finia^® Fill and Finish System as the cell and gene therapy industry evolves toward automation - 14 September 2021

Health Canada Approves Mirasol Pathogen Reduction Technology System to Treat Platelets in Plasma - 18 August 2021

Terumo Blood and Cell Technologies and PhotonPharma, Inc. announce collaboration to develop a novel cancer immunotherapy - 11 August 2021

First-of-its-kind study published on the positive health economic impact of overcoming blood shortages to treat maternal bleeding in sub-Saharan Africa - 29 July 2021

The Spectra Optia^® Apheresis System from Terumo Blood and Cell Technologies in combination with UVA PIT System can now be used to provide extracorporeal photopheresis immunotherapy - 21 July 2021

Terumo Blood and Cell Technologies Joins Cell and Gene Therapy Catapult Process Analytical Technology (PAT) Consortium - 8 June 2021

Terumo Blood and Cell Technologies announces participation in the Connecting the Dots video series, highlighting advanced medical therapies - 26 April 2021

Blood Centers of America Recognizes Outstanding Partners During the COVID-19 Pandemic With Critical Infusion Award - 21 April 2021

Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform - 19 April 2021

Asia Pacific Advanced Therapy Manufacturing & Innovation (ATMI) Grant Winner From Seoul National University College Announced by Terumo Blood and Cell Technologies - 12 April 2021

Terumo Blood and Cell Technologies Grants $50,000 to Support Blood Donor Education Program - 7 January 2021

Convalescent Plasma - An Approach to COVID-19 - 15 December 2020

Lakewood Action Center Set to Provide Grocery Boxes for 5,700 Meals This Thanksgiving - 18 November 2020

Terumo Blood and Cell Technologies Joins Cell Manufacturing Research Initiative to Help Advance Cell Therapy Discoveries - 15 October 2020

Terumo Blood and Cell Technologies to Present at Leading International Event for Regenerative Medicine and Advanced Therapies - 9 October 2020

Swiss Approve Mirasol Pathogen Reduction Technology System to Treat Platelets - 24 September 2020

Terumo Blood and Cell Technologies Announces Advanced Therapy Manufacturing and Innovation (ATMI) Grant 2020 for Asia Pacific - 22 September 2020

Terumo Blood and Cell Technologies Accepting Advancing Apheresis Award 2020 Applications - 18 September 2020

First Lady of Ghana Encourages Healthy Ghanaians to Become Champions of Change and Donate Blood to Save Lives - 7 September 2020

MIPLATE Study Involving Mirasol PRT System - 18 August 2020

Terumo Blood and Cell Technologies’ Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets - 23 April 2020

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide - 22 April 2020

Terumo Blood and Cell Technologies’ Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets - 17 April 2020

COVID-19 Update on Terumo Blood and Cell Technologies’ Manufacturing in Trivandrum, India (Terumo Penpol) - 26 March 2020

Terumo Blood and Cell Technologies' Lakewood, Colorado Operations and COVID-19 - 24 March 2020

Terumo Blood and Cell Technologies & Business Continuity

Tweets by terumobct